Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
J Biopharm Stat. 2024 Jul 3;34(4):526-538. doi: 10.1080/10543406.2023.2234028. Epub 2023 Jul 15.
In recent years, adaptive randomization methods have gained significant popularity in clinical research and trial design due to their ability to provide both efficiency and flexibility in adjusting the statistical procedures of ongoing clinical trials. For a study to compare multiple treatments, a multi-arm two-stage design could be utilized to select the best treatment from the first stage and further compare that treatment with control in the second stage. The traditional design used equal randomization in both stages. To better utilize the interim results from the first stage, we propose to develop response adaptive randomization two-stage designs for a multi-arm clinical trial with binary outcome. Two allocation methods are considered: (1) an optimal allocation based on a sequential design; (2) the play-the-winner rule. Optimal multi-arm two-stage designs are obtained under three criteria: minimizing the expected number of failures, minimizing the average expected sample size, and minimizing the expected sample size under the null hypothesis. Simulation studies show that the proposed adaptive design based on the play-the-winner rule has good performance. A phase II trial for patients with pancreas adenocarcinoma and a germline BRCAPALB2 mutation was used to illustrate the application of the proposed response adaptive randomization designs.
近年来,自适应随机化方法在临床研究和试验设计中得到了广泛的关注,因为它们能够在调整正在进行的临床试验的统计程序方面提供效率和灵活性。对于一项比较多种治疗方法的研究,可以使用多臂两阶段设计来选择第一阶段的最佳治疗方法,并在第二阶段进一步将该治疗方法与对照进行比较。传统设计在两个阶段都采用均等随机化。为了更好地利用第一阶段的中期结果,我们提出了一种用于二分类结局的多臂临床试验的基于反应的自适应两阶段设计。考虑了两种分配方法:(1)基于序贯设计的最优分配;(2)赢家通吃规则。根据三个标准,获得了最优的多臂两阶段设计:最小化预期失败数、最小化平均预期样本量和最小化零假设下的预期样本量。模拟研究表明,基于赢家通吃规则的自适应设计具有良好的性能。使用胰腺腺癌和种系 BRCA1/2 突变患者的二期试验来说明所提出的基于反应的自适应随机化设计的应用。